These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 29128865)
1. Promoter Methylation of RASSF1A indicates Prognosis for Patients with Stage II and III Colorectal Cancer Treated with Oxaliplatin-Based Chemotherapy. Sun X; Yuan W; Hao F; Zhuang W Med Sci Monit; 2017 Nov; 23():5389-5395. PubMed ID: 29128865 [TBL] [Abstract][Full Text] [Related]
2. [Methylation status of PCDH10 and RASSF1A gene promoters in colorectal cancer]. Li M; Yan DG; Liu JL Zhonghua Yi Xue Za Zhi; 2016 Feb; 96(6):456-9. PubMed ID: 26875923 [TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer. Kaneko M; Kotake M; Bando H; Yamada T; Takemura H; Minamoto T BMC Cancer; 2016 Dec; 16(1):945. PubMed ID: 27955637 [TBL] [Abstract][Full Text] [Related]
4. Methylation of RASSF1A and CDH13 genes in individualized chemotherapy for patients with non-small cell lung cancer. Zhai X; Li SJ Asian Pac J Cancer Prev; 2014; 15(12):4925-8. PubMed ID: 24998565 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin. Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772 [TBL] [Abstract][Full Text] [Related]
6. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer. Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007 [TBL] [Abstract][Full Text] [Related]
7. Potential of RASSF1A promoter methylation as a biomarker for colorectal cancer: Meta-analysis and TCGA analysis. Hu F; Chen L; Bi MY; Zheng L; He JX; Huang YZ; Zhang Y; Zhang XL; Guo Q; Luo Y; Tang WR; Sheng MM Pathol Res Pract; 2020 Aug; 216(8):153009. PubMed ID: 32703486 [TBL] [Abstract][Full Text] [Related]
8. MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy. Park JH; Kim NS; Park JY; Chae YS; Kim JG; Sohn SK; Moon JH; Kang BW; Ryoo HM; Bae SH; Choi GS; Jun SH J Cancer Res Clin Oncol; 2010 Aug; 136(8):1135-42. PubMed ID: 20091185 [TBL] [Abstract][Full Text] [Related]
9. Predictive value of unmethylated RASSF1A on disease progression in non-small cell lung cancer patients receiving pemetrexed-based chemotherapy. Deng Q; Su B; Ji X; Fang Q; Zhou S; Zhou C Cancer Biomark; 2020; 27(3):313-323. PubMed ID: 31839603 [TBL] [Abstract][Full Text] [Related]
10. β-catenin and K-ras mutations and RASSF1A promoter methylation in Taiwanese colorectal cancer patients. Chen SP; Wu CC; Huang SY; Kang JC; Chiu SC; Yang KL; Pang CY Genet Test Mol Biomarkers; 2012 Nov; 16(11):1277-81. PubMed ID: 23009572 [TBL] [Abstract][Full Text] [Related]
11. Interrelations of Apoptotic and Cellular Senescence Genes Methylation in Inflammatory Bowel Disease Subtypes and Colorectal Carcinoma in Egyptians Patients. Salama RH; Sayed ZEA; Ashmawy AM; Elsewify WA; Ezzat GM; Mahmoud MA; Alsanory AA; Alsanory TA Appl Biochem Biotechnol; 2019 Sep; 189(1):330-343. PubMed ID: 30989570 [TBL] [Abstract][Full Text] [Related]
12. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients. Honda S; Haruta M; Sugawara W; Sasaki F; Ohira M; Matsunaga T; Yamaoka H; Horie H; Ohnuma N; Nakagawara A; Hiyama E; Todo S; Kaneko Y Int J Cancer; 2008 Sep; 123(5):1117-25. PubMed ID: 18537155 [TBL] [Abstract][Full Text] [Related]
13. DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients. Nilsson TK; Löf-Öhlin ZM; Sun XF Int J Oncol; 2013 Jan; 42(1):127-33. PubMed ID: 23128528 [TBL] [Abstract][Full Text] [Related]
14. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. Wang YC; Yu ZH; Liu C; Xu LZ; Yu W; Lu J; Zhu RM; Li GL; Xia XY; Wei XW; Ji HZ; Lu H; Gao Y; Gao WM; Chen LB World J Gastroenterol; 2008 May; 14(19):3074-80. PubMed ID: 18494062 [TBL] [Abstract][Full Text] [Related]
15. Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Okazaki S; Schirripa M; Loupakis F; Cao S; Zhang W; Yang D; Ning Y; Berger MD; Miyamoto Y; Suenaga M; Iqubal S; Barzi A; Cremolini C; Falcone A; Battaglin F; Salvatore L; Borelli B; Helentjaris TG; Lenz HJ Cancer; 2017 Nov; 123(22):4506-4514. PubMed ID: 28708932 [TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549 [TBL] [Abstract][Full Text] [Related]
17. WNT5A Promoter Methylation Is Associated with Better Responses and Longer Progression-Free Survival in Colorectal Cancer Patients Treated with 5-Fluorouracil-Based Chemotherapy. Jiang G; Lin J; Wang W; Sun M; Chen K; Wang F Genet Test Mol Biomarkers; 2017 Feb; 21(2):74-79. PubMed ID: 28051879 [TBL] [Abstract][Full Text] [Related]
18. Correlations of Promoter Methylation in WIF-1, RASSF1A, and CDH13 Genes with the Risk and Prognosis of Esophageal Cancer. Guo Q; Wang HB; Li YH; Li HF; Li TT; Zhang WX; Xiang SS; Sun ZQ Med Sci Monit; 2016 Aug; 22():2816-24. PubMed ID: 27506957 [TBL] [Abstract][Full Text] [Related]
19. Hypermethylation-modulated downregulation of RASSF1A expression is associated with the progression of esophageal cancer. Mao WM; Li P; Zheng QQ; Wang CC; Ge MH; Hu FJ; Fang XH; Dong ZM; Ling ZQ Arch Med Res; 2011 Apr; 42(3):182-8. PubMed ID: 21722812 [TBL] [Abstract][Full Text] [Related]
20. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study. Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]